Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (23383)	7/20/1998 2:16:00 PM
From: Machaon	Respond to of 32384

<< Maybe in 4 years that connection will be made. >> Ligand could get approval for ONTAK, this year, followed by Panretin Gel. Then in late 1998 or in 1999 they could submit NDA's for Panretin Capsules, Targretin Gel, and Targretin Capsules. Ligand expected profitability in 1999, without the ONTAK drug. The Market may wake up when the dough comes in, and Ligand starts applying it's revenues towards it's deep pipeline development, rather than issuing more shares. Hopefully, LGND will get approval for these NDA's and will become profitable in 1999. Ligand's main target is "off-label" use. The major plan, behind their Panretin and Targretin trials, is aiming square at the "off-label" market, and not necessarily the small markets addressed in the trials, IMHO. So.......... if Ligand is going to be successful, and if LGND shareholders are going to be successful, Ligand's "off-label" approach needs to work. I would be interested in knowing if any other biotech company has been successful in targeting "off-label" markets. Anyway, I think that long term holders are waiting for results of the significant activity and news that is coming out pretty soon. Regards, Bob